Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Mars Petcare acquires AniCura
Mandate

Mars Petcare acquires AniCura

June 13, 2018 M&A

Vinge advises Fidelio Capital in connection with entering into an agreement with Mars Petcare regarding Mars Petcare's acquisition of AniCura.

AniCura was founded in 2011 by Fidelio Capital and The Animal Hospital Foundation in Greater Stockholm through the first merger of companion animal hospitals in the Nordic region. Since then the company grown to become one of Europe’s leading providers of high-quality veterinary care for companion animals and today AniCura has more than 4,000 veterinary professionals who provides modern, high-quality veterinary care for pets at 200 European locations across seven European countries. In 2014, Nordic Capital joined the company as a majority owner, with Fidelio Capital remaining as a significant shareholder. The acquisition is subject to customary regulatory approvals.

Vinge’s team consisted of, among others, Jonas Bergström and Joacim Rydergård.
 

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025